1-3 of 3
Rosa De Cuia
Close
Sort by
Journal Articles

Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,

Roberto Latagliata, Massimo Breccia, Ida Carmosino, Federico Vozella, Paola Volpicelli, Antonietta Ferretti, Giuseppina Loglisci, MD, Michelina Santopietro, Vincenzo Federico, Rosa De Cuia, Daniela Diverio, Mauro Nanni, PhD, Marco Mancini, Giuliana Alimena
Journal: Blood
Blood (2011) 118 (21): 3783.
https://doi.org/10.1182/blood.V118.21.3783.3783
Published: 2011
Journal Articles

Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia: How Important is the Achievement of Complete Cytogenetic Response after 3 Months?

Roberto Latagliata, MD, Massimo Breccia, Ida Carmosino, Federico Vozella, Paola Volpicelli, Caterina Stefanizzi, Michelina Santopietro, Rosa De Cuia, Mauro Nanni, Marco Mancini, Giuliana Alimena
Journal: Blood
Blood (2009) 114 (22): 4271.
https://doi.org/10.1182/blood.V114.22.4271.4271
Published: 2009
Journal Articles

Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.

Roberto Latagliata, MD, Massimo Breccia, MD, Ida Carmosino, MD, Chiara Sarlo, MD, Rosa De Cuia, MD, Marco Mancini, MD, Francesca Biondo, MD, Eleonora Russo, MD, Annalisa De Vellis, MD, Daniela Diverio, MD, Franco Mandelli, PhD, Giuliana Alimena, PhD
Journal: Blood
Blood (2004) 104 (11): 4693.
https://doi.org/10.1182/blood.V104.11.4693.4693
Published: 2004